Associations - FANCA mutation

BIOMARKER:

FANCA mutation

Entrez ID:

Related biomarkers:

‹

›

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

FANCA mutation FANCA mutation	Prostate Cancer Prostate Cancer	rucaparib Sensitive: C2 – Inclusion Criteria rucaparib Sensitive : C2
FANCA mutation FANCA mutation	Prostate Cancer Prostate Cancer	PARP inhibitor Sensitive: C3 – Early Trials PARP inhibitor Sensitive : C3
FANCA mutation FANCA mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	talazoparib Sensitive: C3 – Early Trials talazoparib Sensitive : C3
FANCA mutation FANCA mutation	Colorectal Cancer CRC	sintilimab + fruquintinib Resistant: C3 – Early Trials sintilimab + fruquintinib Resistant : C3